111, Inc. 在2025年问题3中,收入下降了16.7%,但在战略转变和新的AI药物平台的推动下,收入保持盈利。 111, Inc. posted a 16.7% revenue drop in Q3 2025 but stayed profitable, boosted by a strategic shift and a new AI drug platform.

111, Inc.报告说,2025年第三季度财务结果显示,收入下降16.7%,降至30亿元,但第三个连续季度保持了非一般公认的会计原则的盈利能力,业务收入20万元,净收入110万元。 111, Inc. reported third-quarter 2025 financial results showing a 16.7% revenue drop to RMB3.0 billion, but maintained non-GAAP profitability for the third straight quarter with RMB0.2 million in income from operations and RMB1.1 million in net income. 业务支出下降13.4%,降至1.803亿元,该公司本季度的现金流量为38.1亿元。 Operating expenses fell 13.4% to RMB180.3 million, and the company generated RMB38.1 million in operating cash flow for the quarter. 这之后,在剥离三个自营单位(现在满足合作伙伴的需要)后,从战略上转向资产轻型模式,改善流动性。 This follows a strategic shift to an asset-light model after divesting three self-operated units, now fulfillment partners, improving liquidity. “MSANTIANXING”供应链倡议使商品总值提高了20.5%,客户数从Q2增加了31%。 The "MANTIANXING" supply chain initiative boosted gross merchandise value by 20.5% and customer count by 31% from Q2. 该公司计划启动一个AI动力制药采购平台,以提高供应链效率。 The company plans to launch an AI-powered pharmaceutical procurement platform to enhance supply chain efficiency.